Navigation Links
Mass. General team develops potentially safer general anesthetic
Date:7/22/2009

A team of Massachusetts General Hospital (MGH) physicians has developed a new general anesthetic that may be safer for critically ill patients. In the August issue of Anesthesiology, they describe preclinical studies of the drug called MOC-etomidate a chemically altered version of an exiting anesthetic which does not cause the sudden drop in blood pressure seen with most anesthetics or prolonged suppression of adrenal gland activity, a problem with the original version of the drug.

"We have shown that making a version of etomidate that is broken down very quickly in the body reduces the duration of adrenal suppression while retaining etomidate's benefit of keeping blood pressure much more stable than other anesthetics do," says Douglas Raines, MD, of the MGH Department of Anesthesia, Critical Care and Pain Medicine, who led the study.

Almost all general anethetic agents reduce blood pressure immediately after they are administered, which is not a problem for young and healthy patients but can have serious consequences for those who are elderly, critically ill or suffering from blood loss. For such patients, etomidate is often used to induce anesthesia, but since adrenal suppression sets in quickly and can last for several hours to days, other agents are used to maintain anesthesia during a procedure, requiring very careful monitoring to avoid dangerous blood pressure drops.

In their search for a safer version of etomidate, the research team mimicked the chemical structure of other "soft analogue" drugs derivatives of parent drugs designed to be rapidly metabolized by adding a molecule that causes the drug to broken down by natural enzymes soon after producing its effects. Experiments in tadpoles and rats showed that the new agent, MOC-etomidate, quickly produced anesthesia from which the animals recovered rapidly after administration ceased. The rat study verified that MOC-etomidate had little effect on blood pressure levels and no effect on adrenal activity, even when administered at twice the dosage required to produce anesthesia.

The researchers note that, since the study only examined the effect of a single dose of MOC-etomidate, their next step will be to study continuous infusion of the drug. Additional data must be gathered from animal studies before testing the agent in human patients is feasible. "If all goes well, we expect that we could give a large dose of MOC-etomidate to induce anesthesia and then run a continuous infusion to maintain anesthesia without reducing blood pressure in even very sick patients," Raines says. "We also anticipate that patients will wake more quickly and with less sedation after surgery and anesthesia."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Mass. General-based research center will investigate why immune system fails to control hepatitis C
2. Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform
3. Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies
4. Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study
5. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
6. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
7. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
8. LCA Congratulates Nominee For Surgeon General
9. U.S. African Chamber Of Commerce Congratulates U.S. on New Surgeon General, May Improve Health Care for Middle Income Families
10. Pelosi Statement on Appointment of Dr. Regina Benjamin as Surgeon General of the United States
11. Obama Taps Alabama Doctor to Be Surgeon General
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, ... build on a solid foundation. As experts in dangerous situations the Inflow IQ ... coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Force Dagger Foundation the US Special Operations Command’s Patriot Award. The award was ... Thomas thanked Task Force Dagger Foundation for its significant and enduring support to ...
(Date:3/23/2017)... ... 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy and ... published author Bonetta Rose, a wife, mother and grandmother committed to sharing her many ... Publishing, Bonetta Rose‘s new book presents actual events in the life of her family, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an ... published author, Scotty, a fiction writer with an active imagination and an enthusiasm for ... book follows the tale of Wild Bill Hart, who sat looking at the thirty-three ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 2017 Ascendis Pharma A/S (Nasdaq: ASND), a ... address significant unmet medical needs in rare diseases, today ... and webcast on Monday, April 3 during ENDO 2017, ... Orlando, Florida , to discuss new data ... Hormone, TransCon PTH and TransCon CNP). Ascendis ...
(Date:3/23/2017)... - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") ... that AB Laboratories Inc. ("AB Labs") has successfully completed ... the Access to Cannabis for Medical Purposes Regulations ("ACMPR") ... The facility, which was licensed for Cultivation ... at half capacity, with full production capacity scheduled by ...
Breaking Medicine Technology: